cardiovascular disease
Biotech

Novo calls off $598M Heartseed collab, citing 'strategic reviews'

Japanese biotech Heartseed said it was "difficult to reasonably foresee" that Novo would scrap the 2021 deal, despite the pharma's restructuring.
Zoey Becker Sep 30, 2025 1:55pm
weight loss scale weigh measure tape obesity overweight

Pfizer’s new prize Metsera touts 14% weight loss for GLP-1

Sep 30, 2025 6:40am
A close-up view of a jigsaw puzzle with a missing piece

Novo Holdings-backed biotech raises $205M to fill gout care gap

Sep 30, 2025 8:00am
layoffs cuts workforce reduction chairs boxes fired

Sutro loses 3rd of workforce in 2nd round of layoffs this year

Sep 30, 2025 4:16am
direction arrow

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am
Inside the small intestine

Fractyl delivers data on its device for GLP-1 weight maintenance

Sep 30, 2025 12:10pm
More News

Olympus launches AI for spotting polyps in colonoscopy

Sep 30, 2025 11:30am

Fierce Biotech Layoff Tracker 2025: Heidelberg, IO & more

Sep 30, 2025 11:00am

Barinthus enters reverse merger with metabolic disease biotech

Sep 30, 2025 10:39am

Opus sets sights on FDA talks after posting gene therapy data

Sep 30, 2025 9:15am